ERp29 inhibits tumorigenicity by suppressing epithelial mesenchymal transition in gastric cancer

Jing Wu; Yuanyan Yang; Shenshen Gao; Hong Jiang; Xin-Qiong Wang; Yuan Xiao; Xue-Hua Chen; Pu Li; Chun-Di Xu

doi:10.18632/oncotarget.20225

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

ERp29 inhibits tumorigenicity by suppressing epithelial mesenchymal transition in gastric cancer

Jing Wu, Yuanyan Yang, Shenshen Gao, Hong Jiang, Xin-Qiong Wang, Yuan Xiao, Xue-Hua Chen, Pu Li _ and Chun-Di Xu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:78757-78766. https://doi.org/10.18632/oncotarget.20225

Metrics: PDF 1414 views | HTML 1927 views | ?

Abstract

Jing Wu1,2,*, Yuanyan Yang1,*, Shenshen Gao1,3,*, Hong Jiang2, Xin-Qiong Wang1, Yuan Xiao1, Xue-Hua Chen1, Pu Li1 and Chun-Di Xu1

1Department of Pediatrics, Ruijin Hospital and Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

2Department of Oncology, East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

3Department of Human Resource, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Pu Li, email: [email protected]

Chun-Di Xu, email: [email protected]

Keywords: ERp29, EMT, ERK1/2, AKT, gastric cancer

Received: May 04, 2017 Accepted: July 25, 2017 Published: August 12, 2017

ABSTRACT

ERp29 is a novel endoplasmic reticulum (ER) protein that plays an important role in protein unfolding and secretion. Recently, it has been reported to be widely implicated in control of tumorigenesis in some tumors. However, the potential function of ERp29 in gastric cancer remains poorly understood. In this study, we found that the positive rate of ERp29 in gastric cancer tissues was significantly lower than that in adjacent non-tumor tissues. And tumor with high ERp29 expression had inclinations towards smaller tumor size and earlier TNM stage. The in vitro experiments indicated that over-expression of ERp29 in gastric cancer cells significantly suppressed the proliferation and migration of tumor cells, which is consistent with the result of the in vivo animal experiments. Furthermore, our mechanistic investigations revealed that ERp29 reversed EMT process in gastric carcinoma, and its effect was related to the inactivation of ERK1/2 and AKT phosphorylation. Thus, we conclude that ERp29 acts as a tumor suppressor gene in gastric cancer, and is expected to become a novel target of the treatment of GC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20225

Publication Alerts

Research Papers:

ERp29 inhibits tumorigenicity by suppressing epithelial mesenchymal transition in gastric cancer

Abstract